JW Medical Systems Ltd
12
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
25%
3 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
The Effectiveness and Safety of the Coronary Artery Serrated Cutting Balloon Dilation Catheter in the Pre-dilation of Coronary Artery Stenosis Lesions
Role: lead
Treatment of Primary Coronary Artery Vascular Lesions With Biolimus Coated Coronary Balloon Dilation Catheter
Role: lead
Effectiveness and Safety of Coronary Scoring Balloon Dilation Catheter in the Pretreatment of Coronary Stenosis Lesions
Role: lead
The Safety and Efficacy of Biolimus in the Treatment of Patients With in Stent Restenosis
Role: lead
A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery Lesions
Role: lead
EXCEL-II DES to Treat the Patients With de Novo Coronary Artery Lesions. (CREDIT-III)
Role: lead
EXCEL-II Stent Vesus EXCEL Stent to Treat the Patients With de Novo Coronary Artery Lesions.
Role: lead
A Randomized Trial of a Biolimus-Coated Balloon Versus POBA in Small Vessel Coronary Artery Disease
Role: lead
A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT
Role: lead
A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions
Role: lead
Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent
Role: lead
Excel Drug-Eluting Stent Pilot Clinical Registry
Role: lead
All 12 trials loaded